We read with interest the recent communication (1) reporting the efficacy and safety of 3-year treatment with denosumab for osteoporosis in patients with primary biliary cholangitis (PBC). PBC is a chronic cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, portal tract inflammation, and fibrosis that may eventually progress to end-stage liver disease (2). Even though the exact etiology of PBC remains unknown, it is extensively accepted that the development of PBC requires one or more environmental factors that initiate an autoimmune response in genetically predisposed individuals.
Lleo, A., Ma, X., Gershwin, M., Invernizzi, P. (2020). Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. HEPATOLOGY, 72(1), 359-360 [10.1002/hep.31085].
Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
Invernizzi, P
2020
Abstract
We read with interest the recent communication (1) reporting the efficacy and safety of 3-year treatment with denosumab for osteoporosis in patients with primary biliary cholangitis (PBC). PBC is a chronic cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, portal tract inflammation, and fibrosis that may eventually progress to end-stage liver disease (2). Even though the exact etiology of PBC remains unknown, it is extensively accepted that the development of PBC requires one or more environmental factors that initiate an autoimmune response in genetically predisposed individuals.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Letter to the Editor- Might Denosumab Fit in PBC Treatment.pdf
Solo gestori archivio
Tipologia di allegato:
Submitted Version (Pre-print)
Dimensione
1.34 MB
Formato
Adobe PDF
|
1.34 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
